Get In Touch With Us GLP-1 Lawsuit MDL Update (JuneNovember 2025) From June through November 2025, the GLP-1 receptor agonist multidistrict litigation (MDL 3094) expanded rapidly, with the number of pending lawsuits increasing from approximately 1,882 cases in early June to more than 2,900 cases by early November , according to reports from the Judicial Panel on Multidistrict Litigation (JPML)
Related studies have found that GLP-1RAs could limit the growth of prostate cancer by inhibiting the PI3K/AKT/mTOR and ERK/MAPK pathways, while could also limit the growth of pancreatic and prostate cancer cells by inhibiting the NF-kB pathway (210212)
They have a direct effect on egg quality, sperm quality and embryo viability
We are advancing this compound into Phase III development, CEO Brian Lian said in a statement, noting that Viking has received written feedback from an FDA Type C meeting and is currently preparing for an end of Phase II meeting with the agency, which we expect to occur later this year. Final Phase III plans, including design and timeline, will be disclosed after the meeting
Five grams per day added over two weeks is much better tolerated than twenty grams added overnight
What about CagriSema
